Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−12.58 USD
−20.25 M USD
570.00 K USD
1.32 M
About Vaccinex, Inc.
Sector
Industry
CEO
Maurice Zauderer
Website
Headquarters
Rochester
Founded
1997
FIGI
BBG00469NFK4
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of VCNX is 4.40 USD — it has increased by 1.83% in the past 24 hours. Watch Vaccinex, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vaccinex, Inc. stocks are traded under the ticker VCNX.
VCNX stock has risen by 18.13% compared to the previous week, the month change is a 48.08% rise, over the last year Vaccinex, Inc. has showed a −51.65% decrease.
VCNX reached its all-time high on Jan 27, 2020 with the price of 2,568.30 USD, and its all-time low was 1.39 USD and was reached on Oct 8, 2024. View more price dynamics on VCNX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
VCNX stock is 11.40% volatile and has beta coefficient of 0.65. Track Vaccinex, Inc. stock price on the chart and check out the list of the most volatile stocks — is Vaccinex, Inc. there?
Today Vaccinex, Inc. has the market capitalization of 10.74 M, it has increased by 13.92% over the last week.
Yes, you can track Vaccinex, Inc. financials in yearly and quarterly reports right on TradingView.
Vaccinex, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
VCNX net income for the last quarter is −5.73 M USD, while the quarter before that showed −5.63 M USD of net income which accounts for −1.79% change. Track more Vaccinex, Inc. financial stats to get the full picture.
No, VCNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 3, 2024, the company has 40.00 employees. See our rating of the largest employees — is Vaccinex, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vaccinex, Inc. EBITDA is −20.23 M USD, and current EBITDA margin is −3.99 K%. See more stats in Vaccinex, Inc. financial statements.
Like other stocks, VCNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vaccinex, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vaccinex, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vaccinex, Inc. stock shows the sell signal. See more of Vaccinex, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.